Gene therapy for primary immunodeficiencies

Clinical Genetics

Volumn 88, Issue 6, 2015, Pages 507-515

  Fischer, A ^a,b,c,d   Hacein Bey Abina, S ^e,f   Touzot, F ^a,b,c,g   Cavazzana, M ^a,b,c,g  

^a PARIS DESCARTES SORBONNE PARIS CITÉ UNIVERSITY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c IMAGINE INSTITUTE   (France)

^d Centre de Recherche Interdisciplinaire en Biologie   (France)

^e Centre National de la Recherche Scientifique   (France)

^f Groupe hospitalier universitaire Paris Sud   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Gene therapy; Primary immunodeficiencies; Self inactivating retrovirus; Severe combined immunodeficiency; Wiskott Aldrich syndrome

Indexed keywords

RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; CHRONIC GRANULOMATOUS DISEASE; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; VIRAL GENE THERAPY; WISKOTT ALDRICH SYNDROME; CELL DIFFERENTIATION; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; PROCEDURES; REPRODUCIBILITY; RETROVIRIDAE; T LYMPHOCYTE; TRENDS;

CELL DIFFERENTIATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; REPRODUCIBILITY OF RESULTS; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES;

EID: 84946490547     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12576     Document Type: Review

References (94)

1. Al-Herz W, Bousfiha A, Casanova JL et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014: 5: 162.
2. Fischer A, Hacein-Bey S, Le Deist F, Soudais C, Di Santo J. Gene therapy of severe combined immunodeficiencies. Immunol Rev 2000: 178: 13-20.
3. Hong R, Gatti RA, Good RA. Hazards and potential benefits of blood-transfusion in immunological deficiency. Lancet 1968: 2: 388-389.
4. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968: 2: 1364-1366.
5. Gennery AR, Slatter MA, Grandin L et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010: 126: 602-610.e601-611.
6. Pai SY, Logan BR, Griffith LM et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014: 371: 434-446.
7. Moratto D, Giliani S, Bonfim C et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011: 118: 1675-1684.
8. Bertaina A, Merli P, Rutella S et al. HLA-haploidentical stem cell transplantation after removal of alphabeta + T and B cells in children with nonmalignant disorders. Blood 2014: 124: 822-826.
9. Gungor T, Teira P, Slatter M et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014: 383: 436-448.
10. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol 2010: 11: 457-460.
11. Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003: 9: 1131-1137.
12. Hirschhorn R, Yang DR, Puck JM et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency [see comments]. Nat Genet 1996: 13: 290-295.
13. Stephan V, Wahn V, Le Deist F et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med 1996: 335: 1563-1567.
14. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983: 33: 153-159.
15. Williams DA, Lemischka IR, Nathan DG, Mulligan RC. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 1984: 310: 476-480.
16. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986: 6: 2895-2902.
17. Hanenberg H, Xiao XL, Dilloo D et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996: 2: 876-882.
18. Miller AD, Garcia JV, von Suhr N et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991: 65: 2220-2224.
19. Cavazzana-Calvo M*, Hacein-Bey S*, De Saint Basile G et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Equal contribution. Science 2000: 288: 669-672.
20. Hacein-Bey S, Basile GD, Lemerle J, Fischer A, Cavazzana-Calvo M. gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood 1998: 92: 4090-4097.
21. Soudais C, Tusjino S, Sharara LI et al. Stable and functional lymphoid reconstitution common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood 2000: 95: 3071-3077.
22. Otsu M, Anderson SM, Bodine DM et al. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther 2000: 1: 145-153.
23. Hacein-Bey-Abina S, Hauer J, Lim A et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency.* Senior authors. N Engl J Med 2010: 363: 355-364.
24. Gaspar HB, Cooray S, Gilmour KC et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011: 3: 97ra80.
25. Schmidt M, Schwarzwaelder K, Bartholomae C et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007: 4: 1051-1057.
26. Wang GP, Garrigue A, Ciuffi A et al. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 2008: 36: e49.
27. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T Cell proliferation in two patients after gene therapy for SCID-X1. Science 2003: 302: 415-419.
28. Howe SJ, Mansour MR, Schwarzwaelder K et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008: 118: 3143-3150.
29. Larson RC, Lavenir I, Larson TA et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 1996: 15: 1021-1027.
30. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003: 300: 1749-1751.
31. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008: 118: 3132-3142.
32. Hassan A, Booth C, Brightwell A et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood 2012: 120: 3615-3624; quiz 3626.
33. Muul LM, Tuschong LM, Soenen SL et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003: 101: 2563-2569.
34. Gaspar HB, Qasim W, Davies EG et al. How I treat severe combined immunodeficiency. Blood 2013: 122: 3749-3758.
35. Aiuti A, Slavin S, Aker M et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002: 296: 2410-2413.
36. Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009: 360: 447-458.
37. Candotti F, Shaw KL, Muul L et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 2012: 120: 3635-3646.
38. Aiuti A, Cassani B, Andolfi G et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007: 117: 2233-2240.
39. Martins VC, Busch K, Juraeva D et al. Cell competition is a tumour suppressor mechanism in the thymus. Nature 2014: 509: 465-470.
40. Braun CJ, Boztug K, Paruzynski A et al. Gene therapy for Wiskott-Aldrich syndrome - long-term efficacy and genotoxicity. Sci Transl Med 2014: 6: 227ra233.
41. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010: 10: 182-192.
42. Boztug K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010: 363: 1918-1927.
43. Winkelstein JA, Marino MC, Johnston RB Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000: 79: 155-169.
44. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006: 12: 401-409.
45. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010: 16: 198-204.
46. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see comments]. Science 1996: 272: 263-267.
47. Thornhill SI, Schambach A, Howe SJ et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008: 16: 590-598.
48. Modlich U, Navarro S, Zychlinski D et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009: 17: 1919-1928.
49. Biffi A, Bartolomae CC, Cesana D et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011: 117: 5332-5339.
50. Sorrentino B. Assessing the risk of T-cell malignancies in mouse models of SCID-X1. Mol Ther 2010: 18: 868-870.
51. Hacein-Bey-Abina S, Pai SY, Gaspar HB et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 2014: 371: 1407-1417.
52. Biffi A, Montini E, Lorioli L et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013: 341: 1233158.
53. Charrier S, Dupre L, Scaramuzza S et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 2007: 14: 415-428.
54. Scaramuzza S, Biasco L, Ripamonti A et al. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther 2013: 21: 175-184.
55. Astrakhan A, Sather BD, Ryu BY et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012: 119: 4395-4407.
56. Aiuti A, Biasco L, Scaramuzza S et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013: 341: 1233151.
57. Gaspar HB, Buckland K, Rivat C et al. Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency. Mol Ther 2014: 22: S106.
58. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009: 326: 818-823.
59. Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010: 467: 318-322.
60. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Methods Enzymol 2012: 507: 187-198.
61. van Til NP, Sarwari R, Visser TP et al. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome. J Allergy Clin Immunol 2014: 133: 1116-1123.
62. Benjelloun F, Garrigue A, Demerens-de Chappedelaine C et al. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther 2008: 16: 1490-1499.
63. Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci USA 2006: 103: 16406-16411.
64. Santilli G, Almarza E, Brendel C et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011: 19: 122-132.
65. Chiriaco M, Farinelli G, Capo V et al. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther 2014: 22: 1472-1483.
66. Brendel C, Muller-Kuller U, Schultze-Strasser S et al. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 2012: 19: 1018-1029.
67. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009: 10: 578-585.
68. van de Vijver E, van den Berg TK, Kuijpers TW. Leukocyte adhesion deficiencies. Hematol Oncol Clin North Am 2013: 27: 101-116, viii.
69. Bauer TR Jr, Tuschong LM, Calvo KR et al. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency. Mol Ther 2013: 21: 964-972.
70. de Saint BG, Menasche G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 2010: 10: 568-579.
71. Carmo M, Risma KA, Arumugam P et al. Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency. Mol Ther 2014. doi:10.1038/mt2014.242.
72. Booth C, Gilmour KC, Veys P et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011: 117: 53-62.
73. Rivat C, Booth C, Alonso-Ferrero M et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood 2013: 121: 1073-1076.
74. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006: 24: 209-226.
75. Baud O, Goulet O, Canioni D et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001: 344: 1758-1762.
76. Passerini L, Rossi Mel E, Sartirana C et al. CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci Transl Med 2013: 5: 215ra174.
77. Kerns HM, Ryu BY, Stirling BV et al. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood 2010: 115: 2146-2155.
78. Bestas B, Moreno PM, Blomberg KE et al. Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest 2014: 124: 4067-4081.
79. Greene MR, Lockey T, Mehta PK et al. Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line. Hum Gene Ther Methods 2012: 23: 297-308.
80. Girard-Gagnepain A, Amirache F, Costa C et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 2014: 124: 1221-1231.
81. Wang CX, Sather BD, Wang X et al. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 2014: 124: 913-923.
82. Goessling W, Allen RS, Guan X et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011: 8: 445-458.
83. Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010: 329: 1345-1348.
84. Fares I, Chagraoui J, Gareau Y et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014: 345: 1509-1512.
85. Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G. Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells. Nat Biotechnol 2014: 32: 554-561.
86. Riddell J, Gazit R, Garrison BS et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell 2014: 157: 549-564.
87. Sandler VM, Lis R, Liu Y et al. Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature 2014: 511: 312-318.
88. Lucas D, Frenette PS. Stem cells: Reprogramming finds its niche. Nature 2014: 511: 301-302.
89. Fischer A. Gene therapy: repair and replace. Nature 2014: 510: 226-227.
90. Papapetrou EP, Lee G, Malani N et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 2011: 29: 73-78.
91. Lombardo A, Genovese P, Beausejour CM et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007: 25: 1298-1306.
92. Genovese P, Schiroli G, Escobar G et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014: 510: 235-240.
93. Boch J, Scholze H, Schornack S et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009: 326: 1509-1512.
94. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014: 346: 1258096.